When: Breakout above $387 on volume >8M with MACD extension

Then: Starter add of 25-30% with stop at 50 SMA ($358.81)

When: Closing break of 50 SMA at $358.81 on volume >7M shares

Then: Automatic downgrade to UNDERWEIGHT with 10-15% trim; stop on residual at $348

When: Closing break below 200 SMA at $332.67 on above-average volume

Then: Sell residual position (structural break)

When: 30 trading session review window expires without trigger firing and Q4 FY26 earnings approach without margin recovery

Then: Downgrade to UNDERWEIGHT pre-print rather than waiting for catalyst delivery

HOLD - Do not add at current prices; wait for either a pullback to 355-365 zone with stabilized momentum or breakout above 384 on volume exceeding 8M shares; maintain stop discipline at 332.67 (200 SMA)

• Visa trades at 32x trailing P/E against 10.4% EPS growth; forward P/E of 25x implies 27% earnings growth expectations that appear stretched
• Cost of revenue jumped 39% YoY and SG&A jumped 25% YoY, representing structural shift in operating leverage rather than transitory costs
• MACD bearish cross occurred at all-time highs—a momentum divergence that often resolves to the downside
• Aug-24 breakout to 382 on 8.48M shares; subsequent push to 384 printed only 3.82M shares—textbook distribution pattern at resistance
• Hike probability repricing from 30% to 42% in one week signals regime shift; long-duration, high-multiple names like Visa are vulnerable to hawkish surprises
• DOJ trial in 2028 creates ongoing headline risk through depositions, procedural rulings, and expert discovery—not just a 2028 event
• Visa traded at 0.76 beta; defensive profile means it should be reduced when macro regime flips hawkish, not staged into
• Stock has not traded at richer forward multiple except during 2020-2021 froth; current valuation leaves no margin for error
• Staged entry levels of 360, 355, 345 risk maximum exposure into maximum pain if momentum breaks
• Conservative stop at 200 SMA of 332.67; 50 SMA sits at 361.88

→ vs aggressive: Dismissal of 32x trailing multiple and 25x forward P/E by citing business quality ignores that Visa is priced for perfection with less than half the implied growth being delivered—multiple compression risk is real

→ vs aggressive: Framing 39% YoY cost of revenue jump and 25% YoY SG&A increase as 'investment' rather than structural margin compression is intellectual gymnastics; waiting for data confirmation before adding is the disciplined approach

→ vs aggressive: Claim that hawkish Fed is 'already priced in' ignores active repricing: hike probability jumped from 30% to 42% in one week, and 25bp hike is second most likely outcome 13 days from FOMC

→ vs aggressive: Technical 'coiling' narrative glosses over MACD bearish cross at all-time highs and distribution pattern (8.48M shares at 382 versus 3.82M shares at 384)—this is accumulation being misread as accumulation

→ vs aggressive: DOJ '2.5 years of compounding runway' misframes regulatory risk; depositions, procedural rulings, and discovery disputes create market-moving events before 2028 trial, and settlement speculation creates asymmetric downside as well as upside

→ vs aggressive: Staged entry framing of 'win either way' ignores scenario where 345 triggers but trend is broken—maximum exposure into maximum pain

HOLD; conditional staged entries at 360 (RSI reset to 45-50, MACD stabilization), 355 (successful 50 SMA test with volume confirmation), and 345 (trend intact, macro backdrop sound); partial hedging into September 16 FOMC; trim one-third of position if price breaks below 50 SMA at 361.88 on volume exceeding 5 million shares; absolute stop at 200 SMA of 332.67

• Forward P/E of 25x implying 27% earnings growth against actual delivered growth of 10%
• Trailing multiple at 32x against decelerating fundamentals
• Stock priced at upper end of multi-year range
• Cost of revenue jumped 39% YoY
• SG&A jumped 25% YoY
• MACD bearish cross at all-time highs with declining volume is a yellow flag, not a red one
• 50 SMA at 361.88 is intact and serves as trim trigger on high volume
• 200 SMA at 332.67 is the absolute invalidation level
• Beta of 0.76 provides defensive characteristics versus duration-driven names
• Staged entries must be conditional, not mechanical
• Fed hike probability moved from 30% to 42% in a single week; hawkish Fed is not fully priced in
• DOJ trial scheduled for 2028; regulatory risk is real but not binary in near term
• Position already has tail-risk management via stop at 332.67
• Q4 data and Q1 next year are the key catalysts for margin trajectory confirmation

→ vs aggressive: DCF at 92% above fair value cannot be dismissed as 'a single model' when multiple valuation metrics (forward P/E 25x, trailing 32x) all point to stretched valuation

→ vs aggressive: MACD bearish cross is not simply 'noise'—it's a yellow flag that warrants watching, not dismissing

→ vs aggressive: Staged entries without conditions become 'slow-motion bag-hold' if the setup breaks; conditions are essential

→ vs aggressive: Hawkish Fed is not priced in—market repricing is happening actively now with hike probability jumping 12 percentage points in one week

→ vs conservative: Reducing exposure is an overcorrection; the answer is sizing exposure appropriately given binary risk, not abandoning the position

→ vs conservative: Staged entries are not inherently 'leveraged' or a 'recipe for buying into a falling knife'—that framing applies only to mechanical entries without conditions

→ vs conservative: DOJ risk is overstated in near term; V has operated under DOJ scrutiny for years and the trial is in 2028

→ vs conservative: Citing 2021-2022 drawdowns is analytical error when the position already has defined risk parameters via 332.67 stop